Zai Lab Ltd Stock News

Zai Lab collaborated with NovoCure on a study to treat non-small cell lung cancer. There were some concerns about the validity of the study.

SHANGHAI, China and CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the company's senior management team will participate

Many Wall Street analysts still see an economic recovery playing out in China. President Biden recently said he expects relations with China to improve "very shortly.

Company to Host Conference Call and Webcast on May 10, 2023, at 8:00 a.m. ET Company to Host Conference Call and Webcast on May 10, 2023, at 8:00 a.m. ET

Zai Lab will soon launch a handful of new medicines in China. It's also seeking approval for many of its therapies in the U.S. The company also has enough cash to survive even if some of its clinical

Biotech stocks are risky, but high-potential plays can pay off big. Compass Pathways is making progress towards commercializing its first therapy.

Over the next 10 to 20 years, some of healthcare's most impactful innovations will come from biotechnology companies. They'll produce medicines based on living organisms that will save and improve the

Zai Lab Limited (NASDAQ:ZLAB ) Citi Biotech C-Suite Fireside Chat Series Conference Call February 14, 2023 11:00 AM ET Company Participants Josh Smiley - COO Conference Call Participants Yigal Nochomo

Company to Host Conference Call and Webcast on March 2, 2023, at 8:00 a.m. ET Company to Host Conference Call and Webcast on March 2, 2023, at 8:00 a.m. ET

SHANGHAI and CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), today announced that members of the company's senior management team will participate in th

Biotech and medical device stocks can be highly profitable. One of these volatile issues just catapulted over 41%.

Zai Lab Limited Unsponsored ADR (ZLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest furth

A strong phase-3 clinical trial boosted investors' hopes for the Chinese biotech company.

Zai Lab Ltd - ADR ZLAB shares are trading higher by 7.04% to $33.01 Wednesday morning. Shares of Chinese companies at large are trading higher after Chinese regulators reportedly approved a capital ra

SHANGHAI, China and CAMBRIDGE, Mass., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, t